Latest Pharmacy News

LTR Pharma reports a 93% response rate in men seeking convenience and spontaneity with SPONTAN, alongside a 64% response in post-prostatectomy patients, highlighting potential for its rapid-onset intranasal ED treatment in challenging populations.

Elixinol Wellness (ASX: EXL) has posted a record quarterly revenue of A$4.3 million alongside a 45% gross margin, marking a clear shift from its US CBD origins to a diversified Australian wellness platform. Cost reductions and disciplined cash flow management underpin the company’s readiness to scale.

Xenitra Limited (ASX:XEN) has turned around its cash flow in Q4 FY26, reporting positive operating cash flow of A$0.8 million driven by a leaner cost base and a shift towards higher-margin OTC medicines and blockchain-enabled OPAL tokenised sales.

PainChek lifted implemented ARR by 5.9% to $4.46 million and secured its first US commercial contracts under a major Sabra REIT agreement, boosting customer receipts 27% in the June quarter.

Avecho Biotechnology has secured a unanimous recommendation to continue its Phase III insomnia trial without increasing sample size, alongside raising $1.9 million through option exercises and bolstering its cash position to $6.6 million.

Biome Australia capped FY26 with record $23.9 million sales and its flagship probiotic topping Australian pharmacy charts. The company signed an onshore manufacturing deal and expanded its proprietary probiotic clinical trial internationally.

LTR Pharma’s SPONTAN shows rapid absorption in Phase II interim data while securing key US commercial deals for ROXUS, setting the stage for a US market entry later this year.

Elixinol Wellness posted a record quarterly revenue of $4.3 million in Q2 FY26, driven by The Healthy Chef's expansion and a 45% gross margin. Cost cuts helped deliver positive underlying operating cash flow for the third straight quarter despite some one-off expenses.

Biome Australia (ASX: BIO) edged close to breakeven in FY26, driven by $1.8 million in international sales across four markets and a 68% gross margin. The company is set to launch onshore manufacturing and a digital health platform to accelerate growth.

Xenitra has secured a three-year procurement agreement worth at least A$12 million with Kangsheng, a leading Chinese pharmaceutical distributor, marking its OTC pharmaceuticals division's shift from setup to commercial execution.

Adherium reports a near tenfold surge in recurring revenue from remote patient monitoring and clinical evidence supporting significant cost reductions in respiratory care.

Atomo Diagnostics reported a 40% increase in FY26 revenue to $5.3 million, driven by a surge in HIV self-test sales and new OEM customer orders. The company is advancing its syphilis and liver test developments while enhancing manufacturing capacity.